However, combination of YY2 overexpression and anti‐PDL‐L1 therapy reduced both MSI and MSS CRC tumor growth to less than four and sixfold, respectively (Figure 7C; Figure S11C, Supporting Information). Here, YY2 is linked to neoplasm.